Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. (Form: 8-K, Received: 05/22/2017 16:19:53)




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

                                                      

FORM 8-K

                                                      
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 19, 2017

                                                      

ELEVEN BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)

                                                      

 
 
 
 
 
Delaware
 
001-36296
 
26-2025616
(State or Other Jurisdiction
of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)

 
 
 
245 First Street, Suite 1800
Cambridge, MA
 
02142
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (617) 444-8550
None
(Former Name or Former Address, if Changed Since Last Report)

                                                      






Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company      þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                     þ                     


Item 5.07
Submission of Matters to a Vote of Security Holders

Eleven Biotherapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on May 19, 2017. The following is a summary of the matters voted on at that meeting.

 
a)
The stockholders of the Company elected Abbie Celniker, Ph.D., Jane Henderson. and Daniel Lynch. as class III directors, each for a three-year term ending at the annual meeting of stockholders to be held in 2020 and until their respective successors have been duly elected and qualified. The results of the stockholders’ vote with respect to the election of the class III directors were as follows:






Name
 
Votes For
 
 
Votes
Withheld
 
 
Broker Non-    
Votes
 
 
 
 
 
Abbie Celniker, Ph.D.
10,165,378
185,615
9,147,339
Jane Henderson
10,177,628
173,365
9,147,339
Daniel Lynch
10,178,074
172,919
9,147,339


 
b)
The stockholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. The results of the stockholders’ vote with respect to such ratification were as follows:

 
 
 
 
 
 
 
For
 
Against
 
Abstain
 
Broker Non-Votes
19,278,991
 
51,767
 
167,574
 
0






SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
 
 
 
ELEVEN BIOTHERAPEUTICS, INC.
 
 
 
Date: May 22, 2017
 
By:
 
/s/ John J. McCabe
 
 
 
 
John J. McCabe
Chief Financial Officer